Description
Fosinap Pharmacodynamics
ACE inhibitor. It is a prodrug from which the active metabolite fosinoprilat is formed in the body. It is believed that the mechanism of antihypertensive action is related to competitive inhibition of ACE activity, which decreases the rate of conversion of angiotensin I into angiotensin II, which is a potent vasoconstrictor. The decrease in angiotensin II concentration results in a secondary increase in plasma renin activity by eliminating the negative feedback of renin release and directly reducing aldosterone secretion. In addition, fosinoprilat appears to influence the kinin-callicrein system by inhibiting the breakdown of bradykinin.
Due to its vasodilator effect, it decreases RPO (post-load), congestion pressure in the pulmonary capillaries (preload) and resistance in the pulmonary vessels; it increases cardiac minute volume and exercise tolerance.
Indications
Arterial hypertension (also as monotherapy).
Contraindications
Pregnancy, lactation (breast-feeding), hypersensitivity to ACE inhibitors.
Dosage and administration.
- If intravenously administered, the initial dose is 10 mg 1 time/ The dose is further adjusted according to the dynamics of BP; if necessary, the dose can be increased up to 20-40 mg 1 time/ When administered against the background of diuretic therapy, the initial dose of fosinopril should not exceed 10 mg (with close medical supervision of the patient).
- The maximum daily dose when administered orally is 80 mg.
